ShangPharma pumps $60m into Qidong biologics plant for international clients

By Dan Stanton

- Last updated on GMT

Qidong is in the Jiangsu province
Qidong is in the Jiangsu province

Related tags Biotechnology Contract research organization Pre-clinical development

China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.

China Gateway Biologics, the contract manufacturing wing of Shanghai-based pharma firm ShangPharma, will operate the facility located in the Qidong Biopharma Industrial Zone.

“The [$60m] investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale,” ​ShamgPharma’s CEO Michael Hui said in a statement today.

“We strongly believe the state-of-the-art single use facility conforming to Western standards will be able to support our international client base.”

The plant will be equipped with a 500L single-use mammalian cell culture train for clinical phase supply and two 2000L trains for commercial manufacturing, with fill & finish capabilities also available on site.

The facility is the first built in the dedicated Qidong Biopharma Industrial Zone and the investment was described by Qidong's Party Secretary Xu Feng as “a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai.”

The site will also have preclinical research capabilities which will be operated by ChemPartner – ShangPharma’s contract research organisation (CRO) business.

BeiGene in Suzhou

The news comes weeks after Beijing-based biopharma firm BeiGene announced it was building a 9,000m2 cGMP commercial biomanufacturing facility in the Suzhou Industrial Park (SIP) in Suzhou, China – about an hour West of Shanghai.

“This will be a truly cutting-edge, state of the art facility utilizing the leading technologies in biomanufacturing that will also meet the utmost regulatory standards,” ​the firm’s Head of Regulatory Affairs Wendy Yan said in August.

“Upon completion we will seek the necessary approvals to ensure our new site is fully compliant with regulatory procedures in all key global markets, including the United States, Europe and China.”

Related news

Show more

Related products

show more

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

Related suppliers

Follow us

Products

View more

Webinars